Company intelligence / Profile preview
Diverse Biotech
Doylestown, Pennsylvania, United Statesdiversebiotech.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
DBT-12733 demonstrated to be up to 8,000 times more effective than temozolomide (Temodar®) against glioblastoma tumor cells in early testing. The molecule maintained efficacy against temozolomide-resistant glioblastoma cancer cell line T98G. FDA granted Orphan Drug Status for this investigational drug for glioblastoma treatment on May 4, 2020.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesCannabinoid-based drugsAntibody-cannabinoid conjugates
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
The Preston Robert Tisch Brain Tumor Center at Duke University
Beyond the preview
Go deeper on Diverse Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diverse Biotech.